Assessing Packaging Material Interaction During Long-Term Pharmaceutical Storage

Pharmaceutical packaging is not just a passive container; it plays an active role in maintaining product integrity over its shelf life. During long-term storage, interactions between packaging material and the drug product can lead to degradation, contamination, or performance loss. Regulatory guidelines from ICH, FDA, EMA, and WHO emphasize the importance of assessing container-closure systems as part of stability studies. This guide explores how pharmaceutical professionals can evaluate and mitigate packaging-related risks during long-term storage under real-time and intermediate conditions.

1. Why Packaging Interaction Matters in Stability Studies

Packaging material is in constant contact with the pharmaceutical product, especially for oral liquids, injectables, and inhalers. Over time, this can lead to:

• Migration of leachables into the product
• Permeation of moisture, oxygen, or light into the container
• Physical degradation of seals, laminates, or adhesives
• Adsorption of APIs or excipients onto container surfaces

Consequences Include:

• Loss of potency due to oxidation or hydrolysis
• Formation of impurities due to interaction with closure materials
• Incompatibility reactions (e.g., pH shifts, color change)
• Failed container closure integrity over time

2. Regulatory Expectations on Packaging Evaluation

ICH Q1A(R2):

• Requires use of “market-intended container closure system” in stability studies
• Testing must reflect packaging type and configuration

FDA Guidance:

• Mandates evaluation of extractables and leachables for plastics, elastomers, and adhesives
• Expect container-closure integrity testing as part of shelf-life justification

EMA Requirements:

• Supports full material compatibility and performance data in Module 3.2.P.2 and 3.2.P.8
• Expects proof of stability in packaging across entire claimed shelf life

WHO PQ:

• Strong emphasis on protection from humidity, light, and tropical conditions
• Requires Zone IVb stability data in intended packaging

3. Types of Packaging Materials and Their Stability Impacts

Common Packaging Formats:

• HDPE Bottles: High permeability to moisture; often paired with desiccants
• Blister Packs (Alu-Alu or PVC/Alu): Light and moisture barrier varies with material
• Glass Vials and Ampoules: Inert but susceptible to surface delamination in acidic formulations
• Pre-filled Syringes: Potential silicone oil migration; interaction with elastomers
• Plastic Containers (LDPE, PET): Risk of additive leaching or API sorption

Critical Variables:

• Water vapor transmission rate (WVTR)
• Oxygen transmission rate (OTR)
• UV and visible light penetration
• Internal surface chemistry and coating compatibility

4. Designing Long-Term Stability Studies with Packaging Focus

Study Conditions:

• Real-time: 25°C ± 2°C / 60% RH ± 5%
• Intermediate: 30°C ± 2°C / 65% RH ± 5%
• Zone IVb (if applicable): 30°C ± 2°C / 75% RH ± 5%

Study Design Elements:

• Include at least three commercial batches
• Use final marketed packaging configuration (including secondary cartons and leaflets)
• Track container integrity and seal performance over time

Monitoring Parameters:

• Assay and degradation products
• Moisture content and dissolution (for solid or semi-solids)
• Leachables (if identified in extractable studies)
• pH, viscosity, and appearance (for injectables or solutions)

5. Extractables and Leachables (E&L) Studies

These are critical for plastic, elastomeric, and adhesive packaging systems. They assess whether packaging materials might release compounds into the drug product over time.

Definitions:

• Extractables: Potential compounds that may leach out under exaggerated conditions
• Leachables: Actual compounds found in the drug product under storage conditions

Study Flow:

1. Perform material compatibility and extractable profile (typically via GC-MS, LC-MS)
2. Monitor leachables in long-term stability studies using target compound list
3. Assess toxicological impact of detected leachables

6. Case Studies

Case 1: Sorption Issue in PET Bottles

An oral liquid in PET bottles showed a 10% loss in active content after 12 months at 30°C. Further testing revealed sorption of the API onto the PET walls. Packaging was changed to amber glass with rubber liner. Stability profile improved significantly.

Case 2: Leachables in Pre-Filled Syringe System

A biotech product showed appearance changes and impurity growth in syringes stored at 25°C. Investigation confirmed leaching of phenolic antioxidants from the syringe plunger. The supplier material was replaced, and extractables reduced below ICH Q3D thresholds.

Case 3: Blister Laminate Failure in Zone IV

A tablet product in PVC/Alu blisters showed failed moisture content testing in Zone IVb studies. WVTR testing revealed poor humidity barrier. Packaging was upgraded to Alu-Alu format and WHO PQ approved the updated data.

7. Reporting and Documentation

CTD Module Integration:

• 3.2.P.2: Pharmaceutical development, including container-closure system design
• 3.2.P.7: Container closure description and specifications
• 3.2.P.8.1: Summary of stability findings, including packaging interaction results
• 3.2.P.8.3: Stability data tables, E&L results, trend graphs

Tips for Regulatory Clarity:

• Use overlay plots to show data across different packaging types (if applicable)
• Provide analytical method validation for any leachable detection
• Summarize material change justifications and impact on ongoing stability

8. SOPs and Templates for Packaging Interaction Studies

Available from Pharma SOP:

• Packaging Compatibility and Stability Testing SOP
• Extractables and Leachables Study Plan Template
• Packaging System Risk Assessment Checklist
• Container Closure Integrity Testing SOP

Additional insights and regulatory guides are available at Stability Studies.

Conclusion

Packaging plays a decisive role in preserving pharmaceutical product quality over its shelf life. By proactively assessing and monitoring packaging material interactions during long-term storage—particularly under intermediate and tropical conditions—companies can avoid product failures, reduce regulatory risk, and extend market shelf life. Through a well-planned stability study and robust analytical strategy, pharmaceutical professionals can ensure their packaging systems remain as protective as intended, from first release to the final dose.

Compatibility of Drug Formulation with Packaging: A Critical Stability Parameter

Introduction

Packaging systems are more than passive containers—they actively influence the stability, safety, and quality of pharmaceutical drug products. Incompatibility between a formulation and its packaging can result in degradation, loss of potency, or contamination through leachables. Regulatory agencies like the FDA, EMA, and ICH mandate that compatibility be demonstrated through scientifically validated studies. This ensures that no interaction occurs between the formulation and the container-closure system that might compromise safety or efficacy during the product’s shelf life.

This article explores the scientific, regulatory, and technical considerations involved in evaluating the compatibility of drug formulations with their packaging materials, particularly within the context of stability testing and GMP compliance.

Understanding Compatibility in Pharmaceutical Packaging

Definition

Compatibility refers to the absence of any undesirable interaction between the formulation (API + excipients) and packaging materials (container, closure, liners, seals) under normal storage and handling conditions over the product’s shelf life.

Types of Incompatibility

• Chemical interactions: Between drug/excipients and packaging polymers or additives
• Physical effects: Sorption of drug or water vapor, delamination, discoloration
• Migratory issues: Leaching of plasticizers, stabilizers, or ink solvents into formulation

Key Formulation Factors Influencing Compatibility

1. pH and Solvent Polarity

• Formulations with extreme pH or high solvent content (e.g., ethanol, propylene glycol) may extract or degrade packaging components

2. Surfactants and Emulsifiers

• Can facilitate migration of hydrophobic substances from plastic into formulation

3. Oil-Based Formulations

• Risk of extracting plasticizers from LDPE or PVC

4. Temperature Sensitivity

• High storage or transport temperatures accelerate interaction and migration kinetics

Packaging Materials at Risk of Interaction

Plastic Containers

• HDPE: Good moisture barrier, but permeable to gases
• PVC/PVDC: Risk of leaching plasticizers or monomers
• PET: Risk of sorption with oily APIs

Glass Containers

• Type I (Borosilicate): Highly inert, preferred for injectables
• Type III (Soda-lime): Risk of ion leaching with aqueous formulations

Closures and Liners

• Rubber stoppers, silicone oil, and PTFE liners must be tested for extractables and drug interaction

Regulatory Expectations for Compatibility Studies

FDA

• 21 CFR 211.94: Container-closure systems must not alter the safety, strength, quality, or purity of the drug
• FDA Guidance (1999): Compatibility data must be included in NDA/ANDA submissions

ICH

• Q1A(R2): Stability Studies must use proposed market packaging
• Q3B, Q3C: Limits and guidance for impurities and residual solvents

USP

• USP <661.1>: Plastic material characterization
• USP <1664>: Assessment of extractables and leachables

Designing Compatibility Studies

1. Extractables Studies

• Performed under exaggerated conditions to identify potential leachable compounds
• Conditions: high temp, solvents, extended duration
• Techniques: GC-MS, LC-MS, ICP-MS, FTIR

2. Leachables Studies

• Evaluates actual drug product for leached compounds under real-time stability conditions
• Includes multiple time points (0, 3, 6, 12 months, etc.)

3. Sorption Studies

• Measure drug content over time to detect any loss due to adsorption or absorption by packaging

4. Migration Studies

• Study of specific packaging additives (e.g., BPA, phthalates) migrating into formulation

Compatibility Testing in Stability Programs

Inclusion in Stability Protocol

• Use final container-closure system for registration stability batches
• Monitor for degradation products or assay drop
• Assess physical appearance changes (color, odor, precipitation)

Sample Stability Timepoints

• Baseline (0 month)
• Accelerated (3, 6 months)
• Long-term (6, 12, 24 months)

Acceptance Criteria for Compatibility

• No new degradation products outside ICH Q3B limits
• Assay and related substances within 90–110% range
• No visible or measurable changes in appearance, color, pH, or odor
• Leachables below established safety thresholds (e.g., TTC values)

Documentation and SOPs

Essential Records

• Compatibility testing protocol and reports
• Extractables and leachables data
• Packaging specifications and material certifications
• Stability summary reports with packaging conclusions

Key SOPs

• SOP for Drug-Packaging Compatibility Testing
• SOP for Evaluation of New Packaging Materials
• SOP for Qualification of Container-Closure Systems

Case Study: Drug Discoloration Due to Packaging Interaction

A light-sensitive ophthalmic solution in clear PET bottles exhibited color change and assay loss after 6 months under accelerated conditions. Investigation revealed UV-induced degradation. The packaging was switched to amber Type I glass bottles, which blocked UV and preserved drug stability across all timepoints.

Best Practices for Packaging-Formulation Compatibility

• Start compatibility studies early in development
• Use worst-case extractables conditions
• Conduct toxicological assessment of potential leachables
• Always use final commercial packaging in pivotal Stability Studies
• Re-evaluate compatibility when packaging materials or sources change

Auditor Expectations During Inspection

• Compatibility test reports for drug-packaging interaction
• Linkage between stability data and packaging configuration
• Documented risk assessment for leachables
• Change control records for any packaging modifications

Conclusion

Packaging compatibility with drug formulation is a critical component of pharmaceutical development and regulatory approval. It directly influences product stability, patient safety, and shelf life. Through robust extractables, leachables, and compatibility testing strategies—aligned with ICH and GMP expectations—pharmaceutical organizations can mitigate risk and ensure consistent product performance. For test protocols, templates, and evaluation matrices, visit Stability Studies.

Packaging Materials Impact on Pharmaceutical Stability Testing

Introduction

Pharmaceutical packaging materials serve more than a containment role—they are active participants in preserving drug quality, safety, and efficacy. From shielding against moisture, oxygen, and light to ensuring physical protection, packaging materials must be carefully selected and validated to maintain product stability under ICH-recommended conditions. As Stability Studies simulate storage over time, the packaging’s performance becomes a critical determinant of shelf life and regulatory acceptance.

This article examines how packaging materials influence stability study outcomes. We explore different material types, their properties, compatibility with drug substances, regulatory expectations, and strategies for selecting and qualifying packaging materials in the pharmaceutical industry.

Types of Packaging Materials in Pharma

1. Plastics

• HDPE (High-Density Polyethylene): Common for solid oral dosages; good moisture barrier
• LDPE (Low-Density Polyethylene): Flexible; used in tubes and dropper bottles
• PET (Polyethylene Terephthalate): High clarity; used in oral liquids
• PP (Polypropylene): Resistant to heat and chemicals; used in injectable and ophthalmic packaging

2. Glass

• Type I: Borosilicate glass; inert and suitable for injectables
• Type II: Treated soda-lime glass; used for solutions
• Type III: Lower resistance; limited to non-aqueous solutions

3. Foils and Films

• PVC (Polyvinyl Chloride): Basic blister film; low barrier
• PVDC (Polyvinylidene Chloride): High moisture barrier for blister packs
• Aluminum Foil: Total barrier to light, oxygen, and moisture; used in cold-form blisters and sachets

4. Rubber and Elastomers

• Used for stoppers and gaskets; must be inert, non-reactive, and free of extractables

Critical Packaging Material Properties Affecting Stability

1. Moisture Permeability

Moisture ingress is one of the primary causes of degradation in hygroscopic drugs. Packaging must minimize water vapor transmission rate (WVTR), particularly for products stored in ICH Zone IVb (30°C/75% RH).

2. Oxygen Transmission Rate (OTR)

Oxygen-sensitive APIs can oxidize, impacting potency. Oxygen permeability testing is essential when using plastic bottles or films.

3. Light Transmission

Light exposure can degrade photosensitive products. ICH Q1B requires light-protective packaging for susceptible drugs, including amber containers or aluminum foil wraps.

4. Sorption and Leaching

• Sorption: API or excipients adsorb to packaging walls, lowering potency
• Leaching: Packaging components migrate into the product, risking toxicity

5. Thermal Stability

Packaging must withstand thermal cycling without degradation. This is especially relevant during accelerated testing (40°C/75% RH).

Regulatory Expectations for Packaging Materials in Stability

FDA

• 21 CFR 211.94: Containers must not be reactive, additive, or absorptive
• FDA Guidance on Container Closure Systems (1999): Describes testing and documentation expectations

ICH

• ICH Q1A(R2): Stability testing should use the same container-closure system as proposed for marketing
• ICH Q3B/Q3C: Impurities from degradation or leachables must be controlled

WHO

• TRS 961 Annex 9: Stability Studies must reflect real packaging conditions
• Focus on low- and middle-income countries with challenging climates

Material Testing and Validation

Extractables and Leachables Studies (E&L)

These studies identify and quantify potential leachables that can migrate from packaging into the drug product over time.

Testing Approaches

• Use exaggerated conditions (temperature, pH, solvents)
• Techniques: GC-MS, LC-MS, ICP-MS
• Performed for rubber stoppers, plastics, adhesives, inks

Permeation Testing

• Moisture Vapor Transmission Rate (MVTR): For blisters, sachets, bottles
• Oxygen Transmission Rate (OTR): For oxygen-sensitive APIs

Compatibility Studies

• Stress studies to test drug-packaging interactions
• pH stability, degradation profiling, color change monitoring

Packaging Material Qualification and SOPs

Qualification Steps

1. Supplier qualification and COA verification
2. Material ID testing (FTIR, DSC, TGA)
3. Initial extractables study
4. Stability study initiation with final packaging

Essential SOPs

• SOP for Packaging Material Evaluation
• SOP for Extractables and Leachables Testing
• SOP for Packaging Material Specification and Approval
• SOP for Container Closure System Validation

Common Packaging Material-Related Failures

1. Delamination of Foil Blisters

Occurs during high humidity or thermal cycling. Results in compromised barrier properties.

2. Container Crazing or Cracking

Plastic containers may degrade over time or react with solvents.

3. Color Change of Product

Indicates photodegradation due to insufficient light protection.

4. Leachables Above Threshold

Detected during long-term stability; may require a packaging switch or toxicology study.

Case Study: Moisture-Ingress Failure in PVC Blister

A fixed-dose combination tablet exhibited potency drop after 3 months of accelerated stability. Investigation showed high WVTR in standard PVC blisters. PVDC-coated film was substituted, restoring moisture barrier integrity. Retesting confirmed stability, and the new packaging was adopted for global launch.

Packaging Selection Strategy in Stability Programs

1. Start with High-Barrier Materials

Especially for new molecules with unknown sensitivity profiles.

2. Use Marketing-Equivalent Packaging for Registration Batches

Ensures that stability data aligns with what patients will receive.

3. Evaluate Environmental Sensitivity

• Moisture: Use foil or PVDC
• Oxygen: Consider glass or multilayer PET
• Light: Amber glass or UV-resistant plastics

Future Trends in Packaging Materials

• Smart polymers for active barrier response
• Sustainable and biodegradable films
• Digital moisture sensors integrated into packaging
• Automated integrity testing systems

Auditor Expectations

During a GMP Inspection

• Validated packaging specs and test reports
• Supplier change control documentation
• Risk assessment for material substitution
• Consistency between stability samples and marketed presentation

Conclusion

Packaging materials significantly influence pharmaceutical product stability, and their impact must be evaluated thoroughly through compatibility studies, regulatory alignment, and real-time stability testing. By integrating scientifically robust material selection strategies with GMP documentation, pharma companies can ensure product integrity and regulatory compliance across global markets. For SOP templates, test protocols, and packaging qualification checklists, visit Stability Studies.